publication . Article . Other literature type . 2013

Use of Dabigatran for Peri-Procedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation

Mohamed Bassiouny; Walid Saliba; John Rickard; Mingyuan Shao; Albert Sey; Mariam Diab; David O. Martin; Ayman A. Hussein; Maurice Khoury; Bernard Abi-Saleh; ...
Open Access English
  • Published: 03 Apr 2013
Background— Pulmonary vein isolation (PVI) for atrial fibrillation is associated with a transient increased risk of thromboembolic and hemorrhagic events. We hypothesized that dabigatran can be safely used as an alternative to continuous warfarin for the periprocedural anticoagulation in PVI. Methods and Results— A total of 999 consecutive patients undergoing PVI were included; 376 patients were on dabigatran (150 mg), and 623 patients were on warfarin with therapeutic international normalized ratio. Dabigatran was held 1 to 2 doses before PVI and restarted at the conclusion of the procedure or as soon as patients were transferred to the nursing floor. Prope...
Persistent Identifiers
free text keywords: Article, Physiology (medical), Cardiology and Cardiovascular Medicine, Stroke, medicine.disease, medicine, Anesthesia, Atrial fibrillation, Fibrillation, medicine.symptom, Catheter ablation, medicine.medical_treatment, business.industry, business, Warfarin, medicine.drug, Dabigatran, Prospective cohort study, Activated clotting time, medicine.diagnostic_test
Related Organizations
Any information missing or wrong?Report an Issue